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The general anesthetic propofol induces 
ictal-like seizure activity in hippocampal mouse 
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Abstract 
The general anesthetic propofol has been in clinical use for more than 30 years and has become the agent of choice 
for rapid intravenous induction. While its hypnotic and anti-convulsant properties are well known, the propensity for 
propofol to promote seizure activity is less well characterised. Electroencephalogram-confirmed reports of propofol-
induced seizure activity implicate a predisposition in epileptic subjects. The aim of this study was to investigate 
the seizure-promoting action of propofol in mouse brain slices—with the goal of establishing an in vitro model of 
propofol pro-convulsant action for future mechanistic studies. Coronal slices were exposed to either normal artificial 
cerebrospinal fluid (aCSF) or no-magnesium (no-Mg) aCSF—and extracellular field potential recordings made from 
the hippocampus, entorhinal cortex and neocortex. Propofol (and etomidate for comparison) were delivered at three 
stepwise concentrations corresponding to clinically relevant levels. The main finding was that propofol induced ictal-
like seizures in seven out of ten hippocampal recordings (p = 0.004 compared to controls) following pre-exposure to 
no-Mg aCSF—but strongly inhibited seizure-like event (SLE) activity in the neocortex. Propofol did not induce seizure 
activity in slices exposed to normal aCSF. The results support the contention that propofol has the capacity to pro-
mote seizure activity, particularly when there is an underlying seizure predisposition. This study establishes an in vitro 
model for exploring the mechanisms by which propofol promotes subcortical seizure activity.
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Background
Propofol was introduced to clinical practice as a general 
anesthetic in 1977 and has become the agent of choice 
for rapid intravenous induction. It was originally thought 
to be a pure hypnotic (Samra et al. 1995), but has since 
been shown to have strong anticonvulsant properties (al-
Hader et  al. 1992)—the equal of thiopental for treating 
refractory status epilepticus (Prabhakar et al. 2012). The 
pro-convulsant potential of propofol has been debated 
and remains a controversial area (Samra et al. 1995).
Myoclonic activity during propofol anesthesia is com-
mon (Walder et  al. 2002) and many case-studies report 
convulsive-like muscle activity, particularly during 
induction and emergence (Sutherland and Burt 1994). 
Electroencephalographic (EEG) confirmation of cortical 
seizure activity (Hodkinson et al. 1987; Makela et al. 1993; 
Wang et  al. 1997) points to a dual action of propofol—
predominantly anticonvulsant with a weaker pro-convul-
sant effect (Bevan 1993). Where the EEG has confirmed 
seizure activity, subjects with a history of epilepsy tend to 
be overrepresented. For example, Hodkinson et al. (1987) 
report three consecutive cases of propofol-induced epi-
leptiform activity in the EEG of epileptic subjects. In 
a study reviewing five cases of convulsant-like muscle 
activity, the single EEG-confirmed case of seizure activ-
ity was from an epileptic (Makela et al. 1993). In a similar 
study, EEG spikes and sharp waves were recorded in epi-
leptics and non-epileptics following low-dose propofol, 
but the one case of grand mal seizure activity was from 
the former (Wang et  al. 1997). Accordingly, it has been 
recommended that propofol be avoided or used with 
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caution in subjects with a history of epilepsy (Hodkinson 
et al. 1987; Makela et al. 1993; Wang et al. 1997).
Abnormal posturing and convulsive-like movements 
during propofol anesthesia are not universally associated 
with EEG changes consistent with cortical seizure activity 
(Borgeat et al. 1993). These could be instances of non-sei-
zure-related muscle dystonia and/or epileptiform activity 
originating from deeper structures (Borgeat et al. 1993). 
It is noteworthy that subcortical seizure activity, which 
may present as myoclonic convulsive-like movements 
(Gale 1992), can be difficult to detect in the EEG (Borgeat 
et al. 1993; Kiloh and Osselton 1961; Makela et al. 1993). 
Furthermore, focal epileptiform events that are spatially 
limited may only be detectable with high-density elec-
trocorticogram recordings. Thus, a normal EEG does not 
necessarily preclude an epileptiform aetiology.
With this as background, we designed a series of exper-
iments to investigate the seizure-promoting action of 
propofol in mouse brain slices. The goal was to establish 
an in vitro model of propofol pro-convulsant action that 
could be probed for specific mechanisms in future stud-
ies. Three questions were of paramount interest. Firstly, 
could we identify a pro-seizure effect of propofol in the 
slice model? Secondly, could the apparent in  vivo sus-
ceptibility of epileptics to propofol-induced seizures be 
replicated? Thirdly, are cortical or subcortical regions 
differentially sensitive to propofol seizure promoting 
effects? Slices were pre-exposed to no-magnesium condi-
tions—initiating ongoing seizure-like events (SLE) akin 
to in vivo interictal activity—and compared to quiescent 
slices exposed to “normal” conditions. We focussed on 
three anatomical regions, the hippocampus, entorhi-
nal cortex and the neocortex. The former is of particu-
lar interest as the site of seizure generation in temporal 
lobe epilepsy (Das et al. 2009) and as a documented tar-
get for anesthetic excitatory effects (Becker et  al. 2012). 
The entorhinal area is also a seizure-prone region by 
nature of its recurrent network structure (Dhillon and 
Jones 2000). Finally, we compared the effect of propo-
fol to that of etomidate, which shares with propofol a 
gamma-aminobutyric acid (GABA)-receptor mechanism 
of action (Lingamaneni and Hemmings 2003). We choose 
etomidate as a comparator because it is recognised as 
having pro-seizure characteristics (Modica et  al. 1990) 




Slices perfused with no-Mg aCSF generated spontane-
ous interictal-like SLE activity characterised by a sharp 
positive or negative deflection in the field potential of 
approximately 100 μV peak–peak amplitude and of 1–2 s 
duration (illustrated in Fig.  1). On some occasions this 
initial population “spike” was followed by oscillatory 
activity of lower amplitude, lasting up to approximately 
5 s in the neocortex (see Tables 1, 2). Longer oscillatory 
activity was recorded in the entorhinal cortex compared 
to both the hippocampus (p < 0.001) and the neocortex 
(p  <  0.05). The frequency of baseline SLE activity was 
significantly higher in recordings from the hippocampus 
compared to the entorhinal cortex (p  <  0.001) and the 
neocortex (p < 0.001). No statistical difference was seen 
in baseline amplitude between the different brain regions.
Effects of propofol on no‑Mg SLE activity
Recordings during propofol administration showed 
highly variant changes in activity in the three investigated 
areas. Most dramatically, in the hippocampus propo-
fol induced a transition from interictal-like SLE activity 
characterised by intermittent unitary sharp waves—to 
prolonged ictal-like seizure events. The characteristics of 
the latter were not identical in all hippocampal record-
ings, but two different groups with similar patterns could 
be identified. In one group (n  =  4) the events started 
with a period of high frequency “tonic-like” activity that 
transitioned into “clonic-like” oscillations before termi-
nating (see Fig. 2). On average one event occurred every 
2–3 min, with a mean length of 196 s. In the other group 
(n  =  3), oscillation frequency tended to remain stable 
throughout the event. They also occurred every 2–3 min, 
but had a shorter mean length of 37  s. Following drug 
washout, the majority of the recordings returned to the 
interictal-like activity pattern that was established during 
baseline. Seven out of ten of the propofol hippocampal 
recordings exhibited this transition to ictal-like seizure 
Fig. 1 An example of no-magnesium seizure-like event (SLE) activity 
showing an expanded time view on the left and an enlarged view of 
a single SLE on the right
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activity, compared with none of eight controls perfused 
with drug-free no-Mg aCSF (p  =  0.004, Fisher’s exact 
test). No ictal-like events occurred in slices perfused with 
propofol vehicle (20 % intralipid).
In the two other investigated areas, the entorhinal cor-
tex and the neocortex, no transition to ictal-like seizures 
were seen during propofol perfusion. A strong decrease 
in event frequency was seen after drug administration in 
both the entorhinal cortex (p  <  0.0001) and the neocor-
tex (p  <  0.0001) (Table  1). Figure  3 illustrates the pro-
found inhibitory effect of propofol on cortical interictal 
SLE activity; compared with the ictal events precipitated 
in the hippocampus (see Fig.  2). Propofol had contrast-
ing effects on SLE length and amplitude in the entorhinal 
and neocortical regions. In the former, propofol increased 
the length of SLEs (p = 0.0155), while in the neocortex it 
induced a significant (p = 0.0302) increase in SLE ampli-
tude. These changes were not seen in the control slices 
perfused with no-Mg aCSF without drug delivery. Rather, 
SLE frequency during control recordings tended to 
increase with time, in keeping with previous studies (Voss 
et al. 2010).
Table 1 Median (range) changes in SLE-characteristics during propofol administration
* p values generated from repeated measures analysis of variance (ANOVA)
** p values generated from Freidman test (nonparametric repeated measures ANOVA)
a p < 0.001 compared to baseline, Tukey–Kramer multiple comparison test
b p < 0.05 compared to baseline, Tukey–Kramer multiple comparisons test
c p < 0.05 compared to baseline, Dunn’s multiple comparisons test
d p < 0.001 compared to baseline, Dunn’s multiple comparisons test
Location Baseline Last dose End period P value
Entorhinal cortex
 Amplitude (µV) 92.5 (23.7–341.9) 111.3 (25.9–310) 96 (36.6–429) ns
 Frequency (/min) 2.0 (1.3–4.9) 0.7 (0.3–1.1)a 0.7 (0.3–1.4)a <0.0001*
 Length (s) 3.6 (1.1–9.9) 9.1 (1.0–51.5) 18.9 (1.1–49)b 0.0155*
Neocortex
 Amplitude (µV) 138.7 (37–494) 245.7 (34.3–615)c 229.4 (38.8–429.2) 0.0302*
 Frequency (/min) 2.5 (0.6–4.4) 0.6 (0.0–3.6)d 0.7 (0.1–4.5)d <0.0001**
 Length (s) 2.3 (1–5.1) 1.9 (0–12.6) 1.8 (1–6.5) ns
Table 2 Median (range) changes in SLE-characteristics during etomidate administration
* p values generated from repeated measures analysis of variance (ANOVA)
** p values generated from Freidman test (nonparametric repeated measures ANOVA)
a p < 0.01 compared to baseline, Tukey–Kramer multiple comparisons test
b p < 0.001 compared to last dose, Tukey–Kramer multiple comparisons test
c p < 0.01 compared to baseline, Dunn’s multiple comparisons test
d p < 0.05 compared to baseline, Dunn’s multiple comparisons test
Location Baseline Last dose End period P value
Entorhinal cortex
 Amplitude (µV) 79.9 (28.3–229.8) 95.7 (20.8–172.9) 108.0 (30.0–199.3) ns
 Frequency (/min) 2.7 (0.4–4.0) 1.2 (0.2–1.9)a 2.7 (0.5–6.5)b 0.0004*
 Length (s) 2.9 (2.1–143.3) 2.5 (1.0–246.6) 3.4 (1.3–73.7) ns
Neocortex
 Amplitude (µV) 136.6 (46.8–502.6) 178.5 (75.0–663)c 141.2 (67.4–633.0) 0.0084**
 Frequency (/min) 3.4 (3.2–5.2) 1.3 (0.3–3.4) 3.7 (0.7–12.7) 0.0515**
 Length (s) 2.2 (1.2–3.4) 1.5 (1.1–1.7) 1.7 (1.5–3.6) ns
Hippocampus
 Amplitude (µV) 90.1 (11.8–280.5) 103.8 (11.9–428.6) 135.1 (14.3–346.6)d 0.0398*
 Frequency (/min) 5.8 (3.5–7.9) 2.1 (0.1–5.1)c 4.5 (2.3–17.6) 0.0013**
 Length (s) 1.1 (1.0–3.2) 1.2 (0.9–1.7) 1.2 (1.0–3.2) ns
Page 4 of 9Voss et al. SpringerPlus  (2015) 4:816 
Fig. 2 Propofol-induced ictal-like bursting activity in the hippocampus showing a changing pattern of the frequency and amplitude of popula-
tion activity within each burst. The top illustration shows a full recording of approximately 9 h. The three lower pictures are enlargements of the grey 
squares and illustrate: 1 interictal seizure-like event (SLE) activity before propofol administration; 2 ictal-like burst during propofol administration 
with a biphasic change in frequency and amplitude and; 3 end period where the SLE-activity is returning to the interictal SLE-activty pattern estab-
lished during baseline
Fig. 3 A full length recording showing the inhibitory effect of propofol on interictal seizure-like event (SLE) activity in the neocortex. This recording 
further illustrates the increase in event amplitude prior to cassation of activity
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Effects of etomidate on no‑Mg SLE‑activity
One out of ten hippocampal recordings showed a tran-
sition to an ictal-like seizure pattern after etomidate 
administration, a rate not significantly different from the 
control recordings. The ictal-like pattern had the same 
characteristics as shown in Fig. 2 for propofol.
Otherwise, etomidate had a similar effect on no-Mg 
SLE activity in all three brain areas (see Table  2). A 
reduction in event frequency was seen in all three loca-
tions, although for the neocortex the frequency drop 
was not quite significant (p = 0.0515), due to a paradoxi-
cal increase in SLE frequency in one recording during 
perfusion of the highest etomidate dose. Like propofol, 
etomidate induced a significant increase in SLE ampli-
tude in the neocortex (p = 0.0084), as well as in the hip-
pocampus (p = 0.0398). Etomidate induced no significant 
changes in the length of SLEs in any location. None of 
these changes were seen in any of the control slices per-
fused with no-Mg without drug delivery.
Propofol and etomidate effects on slices perfused 
with normal aCSF
Neither propofol nor etomidate induced any sign of SLE 
activity in recordings from slices perfused with normal 
aCSF. That is, these slices remained quiescent for the full 
duration of the recordings, at all locations.
The aim of this study was to investigate whether pro-
seizure effects of the general anesthetic propofol could 
be identified in the in  vitro cortical slice—and whether 
seizure susceptibility was related to the prior state of the 
tissue and/or anatomical location. Most notably, propofol 
consistently induced prolonged ictal-like seizure events 
in the hippocampus following pre-exposure to no-Mg 
aCSF. The hippocampal ictal-like events closely resembled 
tonic–clonic seizures recorded from the electroencephalo-
gram in vivo (Jensen and Yaari 1997). The results support 
in  vivo findings showing that propofol has the capacity 
to promote seizure activity—and suggest that subcortical 
regions may be particularly susceptible. The pro-seizure 
effects were observed on a background of epileptiform 
“spiking” activity induced by magnesium removal from the 
aCSF, a state that can be likened to the interictal epilep-
tic brain. Thus, the results are also consistent with in vivo 
studies showing that propofol is more likely to promote 
epileptiform activity when there is an underlying seizure 
predisposition (Hodkinson et al. 1987; Makela et al. 1993; 
Wang et al. 1997). In addition, propofol strongly inhibited 
SLE activity in the neocortex, confirming its dual anti- and 
pro-convulsant properties (Bevan 1993).
By comparison, etomidate evoked few excitatory effects 
within the slice. It shared with propofol a tendency to 
enhance SLE amplitude in the neocortex and hippocam-
pus, but otherwise reduced the frequency of SLE activity 
in all investigated areas. This was surprising on two levels. 
Firstly, etomidate and propofol are thought to share a sim-
ilar GABAergic mechanism of action (Franks 2006); and 
secondly, etomidate is more well-known than propofol for 
its pro-seizure effects (Modica et  al. 1990). An explana-
tion for this difference is not forthcoming from this study, 
although a number of speculative hypotheses could be 
postulated. These include, but are not limited to: localised 
hippocampal expression of GABAA subtypes that are dif-
ferentially sensitive to etomidate and propofol; differences 
in the capacity for propofol and etomidate to directly acti-
vate GABAA receptors and; differential effects of propofol 
and etomidate on NaKCC1 and KCC2 chloride transport-
ers such that a chloride imbalance is facilitated by the 
former. However, the balance of evidence does not lend 
strong support to any one of these. For example, while 
α4 and α5-containing GABAA receptors show enhanced 
expression in the hippocampus compared to the cerebral 
cortex (Sieghart and Sperk 2002), etomidate and propofol 
exhibit similar activation profiles for these GABAA sub-
types (Bai et  al. 2001; Caraiscos et  al. 2004; Meera et  al. 
2009). Furthermore, both propofol and etomidate directly 
activate GABAA to approximately 25 % of the maximum 
current induced by endogenous GABA (Siegwart et  al. 
2002). Finally, the only documented effect of propofol 
on chloride handling is facilitation of KCC2 (Wang et al. 
2006), which would tend to limit the development of 
depolarising GABAA effects.
Although widely thought to act specifically on GABAA 
receptors, propofol has additional actions that could con-
tribute to its propensity to induce excitatory effects. Three 
possibilities present themselves. Firstly, reports indicate 
that glutamatergic effects may be relevant to propofol’s 
mechanism of action (Yiqing et  al. 2014). In particular, 
propofol increases GluA1 AMPA receptor phosphoryla-
tion at serine 831 (S831) in the mouse hippocampus but 
not in the prefrontal cortex (Mao et al. 2014). S831 phos-
phorylation in GluA1 AMPA-receptors increases sin-
gle channel conductance (Jenkins and Traynelis 2012) 
and potentiates LTP (Wang et  al. 2014). This represents 
a promising, but as yet untested potential mechanism 
for propofol-mediated, hippocampal-specific excitatory 
effects. Secondly, Schwieler et al. have shown that propo-
fol is an agonist of metabotropic GABAB-receptors 
(Schwieler et  al. 2003). Interestingly, baclofen (a GABAB 
agonist) inhibits hippocampal inter-ictal activity, but in 
so doing facilitates ictal-like activity (Swartzwelder et  al. 
1987), an effect remarkably similar to that observed in 
our study. We have shown in unrelated experiments that 
the GABAB agonist baclofen enhances the length of SLE 
activity in the neocortex (unpublished data). An excita-
tory GABAB effect could be mediated by a pre-synaptic 
GABAB autoreceptor action that acts to inhibit the release 
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of GABA (Dugladze et  al. 2013). Finally, propofol inhib-
its hyperpolarisation-activated cation currents (Ih) in 
both cortical (Chen et al. 2005) and hippocampal (Funa-
hashi et  al. 2004) regions. This is an important point of 
distinction between propofol and etomidate, as the latter 
does not block Ih (Chen et al. 2009). A reduction in Ih has 
been implicated as a mechanism supporting epileptogen-
esis (Wierschke et al. 2010), which could occur secondary 
to an increase in neuronal input resistance resulting in 
enhanced EPSP amplitude (Magee 1998); and/or a loss of 
membrane stabilisation resulting in prolongation of oscil-
latory field potential activity (He et al. 2014).
The no-magnesium in vitro slice model was used in this 
study because it is a recognised and widely used method 
to investigate mechanisms of epilepsy (Isaev et al. 2012; 
Liu et  al. 2010). In particular, the pattern of no-magne-
sium SLE activity resembles the interictal state in epilep-
tics. The inherent limitations of an in vivo animal model 
such as this are countered by the ability to stringently 
control experimental conditions and isolate effects and 
mechanisms to particular structures. In the case of this 
study it allowed us to differentiate effects to the hip-
pocampus and cerebral cortex in complete isolation from 
subcortical influences.
Conclusions
In conclusion, the results support the contention that 
propofol has the capacity to promote seizure activity, par-
ticularly in the hippocampus and when there is an under-
lying seizure predisposition. The mechanism by which 
this occurs is not clear, but appears to be independent 
of the seizure-promoting action of etomidate. This study 
establishes a model for exploring the mechanisms by 
which propofol promotes subcortical seizure activity.
Methods
The method of euthanasia was approved by the Waikato 
Ethics Committee at the University of Waikato, Hamil-
ton, New Zealand.
Preparation of slices
Brain slices were investigated from 30 wild type mice of 
C57, 129SV and C57/129SV genetic background. The 
animals were 1–6 months old, both sexes and kept with 
unlimited access to water and food in a 12-h day/night 
cycle. All age ranges were represented in all experimental 
groups.
The mice were anesthetised with carbon dioxide and 
the brain dissected and transferred directly to ice-cold 
carbogenated (95  % O2, 5  % CO2) “normal” artificial 
cerebrospinal fluid (aCSF) composed of 125  mM NaCl, 
2.5  mM KCl, 1  mM MgCl2, 2  mM CaCl2, 1.25  mM 
NaH2PO4, 26  mM NaHCO3 and 10  mM glucose. To 
maximise the number of slices containing the hippocam-
pus, the brain was sectioned (400 μm, Campden Instru-
ments Ltd, Sileby, Leics, UK) coronally between Bregma 
0 to −5 mm. Thereafter, the slices were allowed at least 
1 h of recovery at room temperature (19–23 °C) in either 
normal aCSF or magnesium-free (no-Mg) aCSF, depend-
ing on the experiments. No–Mg aCSF was composed 
of 124  mM NaCl, 5  mM KCl, 2  mM CaCl2, 1.25  mM 
NaH2PO4, 26  mM NaHCO3 and 10  mM glucose. The 
aCSF solutions were used for no longer than 1 week fol-
lowing storage at 1–4 °C.
Electrical recording of field potential activity
After recovery, one slice at a time was physically divided 
using a scalpel blade to isolate the cerebral cortex from 
the hippocampus; and one hemisphere from the other 
(see Fig.  4). This was to ensure that recordings from 
the cerebral cortex were independent of the hippocam-
pus and vice versa. Each slice was then transferred to a 
submersion-style bath perfused with carbogenated nor-
mal or no-Mg aCSF, depending on the experiment being 
performed. Perfusion was by gravity feed at a flow rate of 
5  ml/min. The flow rate was checked repeatedly during 
the recordings to ensure it remained stable.
Extracellular field potential activity was recorded from 
one to three 25 µm Teflon-coated tungsten electrodes, posi-
tioned in the neocortex, entorhinal cortex and hippocam-
pus. For the neocortex no particular subregion was targeted 
and included the posterior parietal association, retrosple-
nial, primary somatosensory, primary motor, piriform, 
visual and auditory cortical areas. In the hippocampus elec-
trodes were placed in the CA1, CA3 or dentate gyrus areas.
Fig. 4 Picture of a mouse brain slice with each of the recording 
regions numbered adjacent to the respective electrodes. The lines 
illustrate where the slice was physically sectioned to isolate the cortex 
from the hippocampus. 1 the neocortex, 2 the hippocampus and 3 
the entorhinal cortex
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Recordings were amplified (1000×, A-M Systems, USA 
or 250×  Kerr Tissue Recording System, Kerr Scientific 
Instruments, Christchurch, New Zealand), AD-converted 
(Power 1401, CED, UK or PowerLab, ADInstruments, Syd-
ney, Australia) and stored on computer (Spike2, CED, UK 
or LabChart, ADInstruments, Sydney, Australia) for later 
offline analysis using MatLab software. The recordings 
were low-pass filtered at either 1000 or 100 Hz (CED and 
PowerLab, respectively) and high-pass filtered at 1 Hz. All 
of the experiments were performed in a Faraday shielded 
room to minimize electrical noise in the recordings.
Drug preparation and delivery
Propofol was prepared as a 1 % solution of 2,6 diisopro-
pylphenol 97+ % (SAFC supply solutions, USA) in 20 % 
Intralipid (Fresenius Kabi AB, Sweden) and etomidate 
as the commercially available Hypnomidate solution 
(Janssen-Cilag, Belgium). The drug concentrations used 
were 28, 56 and 84 μM for propofol and 8, 16 and 24 μM 
for etomidate. In each case the appropriate amount of 
each drug was added directly to pre-carbogenated aCSF. 
The concentrations were calculated to give tissue levels 
similar to that achieved clinically for surgical anesthe-
sia, based on the diffusion charactersitics of etomidate 
into brain slice tissue and the relative clinical potencies 
of etomidate and propofol. Thus, at a slice recording 
depth of 100–200 μm, it takes approximately 10–15 min 
for the tissue concentration of etomidate to reach half 
of the drug concentration in the perfusion bath (Benk-
witz et  al. 2007). For our lowest etomidate concentra-
tion this equates to a tissue concentration of 4  μM. In 
rodents, a brain effect-site etomidate concentration of 
13  μM induces a surgical level of anesthesia (De Paepe 
et  al. 1999). Our relatively higher propofol concentra-
tions were based on clinical data showing that etomidate 
is approximately five times more potent than propofol 
(Avramov et al. 1995).
Experimental protocols
Experiments were performed in either normal or no-Mg 
aCSF. In the case of the former, no baseline SLE activity 
was established in the tissue, according to standard prac-
tice. Under these conditions, viable tissue shows a tran-
sient burst of high frequency activity (see Fig.  5) when 
an electrode is inserted into the tissue (Voss et al. 2013). 
All recordings in normal aCSF showed this characteris-
tic response. When using no-Mg aCSF, SLE activity was 
already established in the tissue and recordings were made 
from locations where robust and stable activity was found. 
In these cases, at least 10  min of stable SLE activity was 
recorded prior to delivery of the first anesthetic concentra-
tion. A corresponding “baseline” time-period was allowed 
for slices in normal aCSF. Thereafter, either propofol 
(n = 27 in no-Mg and n = 7 in normal aCSF) or etomidate 
(n = 19 in no-Mg and n = 12 in normal aCSF) were deliv-
ered at three increasing concentrations at 30 min intervals.
The no-Mg experiments were terminated when either 
the maximum anesthetic concentration was reached or 
SLE frequency dropped to 50 % of that established dur-
ing baseline. When one of these criteria was met for all 
recordings in the slice, wash-out with drug-free aCSF fol-
lowed. Wash out was continued for 40  min or until the 
return of SLE activity could be confirmed.
To control for the possibility of time effects: 3 slices 
were perfused with no-Mg aCSF with addition of three 
consecutive doses of drug-free 20  % intralipid solution 
equivalent in amount to the propofol experiments; and 
13 slices were perfused with no-Mg aCSF for at least 3 h 
without delivery of anesthetic.
All slices were photographed and recording locations 
identified in consultation with the Allen Interactive Brain 
Atlas.
Statistical analysis
For 36 out of a total of 178 recording locations, the pro-
tocol was not completed for one or other of the following 
reasons:
1. 10 min of stable baseline no-Mg SLE activity was not 
achieved.
2. Return of stable no-Mg SLE activity was not achieved 
during drug wash out,
3. A burst of activity with electrode insertion could not 
be identified in normal aCSF recordings.
Fig. 5 Illustration from one slice perfused with normal artificial 
cerebrospinal fluid (aCSF) showing a burst of high frequency activity 
upon electrode insertion. This characteristic response was used as a 
gauge of tissue viability in slices perfused with normal aCSF, which do 
not ordinarily express seizure-like event activity
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4. Stable no-Mg SLE activity could not be achieved for a 
minimum of three hours during control recordings.
5. Electrodes were inadvertently moved during record-
ing.
These recordings were excluded from the study, giving 
a total of 142 recordings for statistical analysis.
During the course of the experiments, it became 
apparent that propofol was inducing a unique pattern of 
activity in the majority of hippocampal recordings, char-
acterised by a transition from interictal-like SLE activity 
into long ictal-like bursts (see “Results and discussion” 
for details). The propofol hippocampal data was therefore 
analysed as a separate group by quantifying the propor-
tion of recordings exhibiting ictal-like bursting versus 
interictal-like SLE activity using the Fisher’s exact test. 
The qualitative characteristics of these recordings were 
assessed in detail.
The remainder of the data were analysed in MatLab for 
changes in SLE amplitude, frequency and length. Back-
ground noise and artefacts were first removed by visual 
inspection. The data were then quantified and averaged 
over three time periods covering:
1. Baseline 10 min before drug delivery.
2. Last dose 30  min during perfusion of either the 
maximum drug concentration or that concentration 
required to effect a 50 % reduction in SLE frequency. 
The 30 min analysis period was offset by 10 min from 
the start of perfusion of the relevant concentration, 
since at a flow rate of 5 ml/min, 10 min is needed for 
the drug concentration in the perfusion bath to equil-
ibrate (data not shown).
3. End period the last 30–40 min of recording following 
drug washout.
In the control slices, corresponding time frames were 
selected. For a small proportion of recordings (10 out 
of 142) the automated MatLab scripts failed to accu-
rately report SLE length. In these cases SLE length was 
manually quantified and averaged across five sequen-
tial SLEs corresponding to equivalent time points in the 
recordings.
Graphpad (GraphPad Software Inc 2003, v3.06) was 
used for all statistical analyses. Data normality was tested 
using the Kolmogorov–Smirnov test, and parametric or 
non-parametric ANOVA and pair-wise tests applied as 
appropriate. The data are presented as median (range). A 
P value <0.05 was considered statistically significant.
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